Minor neuropsychological deficits and stage 2 of Alzheimer's disease.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stark Melina, Wagner Michael, Kuhn Elizabeth, Roeske Sandra, Amthauer Holger, Bartels Claudia, Boecker Henning, Brosseron Frederic, Buchert Ralph, Buerger Katharina, Daamen Marcel, Drzezga Alexander, Düzel Emrah, Ersözlü Ersin, Essler Markus, Ewers Michael, Fliessbach Klaus, Glanz Wenzel, Hellmann-Regen Julian, Incesoy Enise I, Janowitz Daniel, Kafali Konstantinia, Kilimann Ingo, Krause Bernd Joachim, Kronmüller Marie, Laske Christoph, Maier Franziska, Maurer Angelika, Michely Jochen, Perneczky Robert, Peters Oliver, Preis Lukas, Priller Josef, Rauchmann Boris-Stephan, Reimold Matthias, Rominger Axel, Schmid Matthias, Schneider Anja, Sodenkamp Sebastian, Spottke Annika, Spruth Eike Jakob, Teipel Stefan, Wiltfang Jens, Alzheimer´s Disease Neuroimaging Initiative (ADNI), Jessen Frank, Kleineidam Luca
Аннотация
METHODS: We pooled data from cognitively normal individuals participating in three longitudinal cohort studies (N = 13,192, 8,359[63.3%] female, mean [SD] age 71.0[8.4]).
RESULTS: Compared to participants without SCD and MNPD (SCD-/MNPD-), SCD-/MNPD+, SCD+/MNPD-, and SCD+/MNPD+ participants had an increased risk for mild cognitive impairment (MCI) and dementia, including in amyloid-positive individuals. Focusing on SCD+/MNPD+ participants triples the positive predictive value of amyloid biomarker testing for the 5-year prediction of MCI and reduces the required samples size for trials in preclinical AD to one fourth, compared to considering all cognitively normal participants regardless of subtle symptoms.
DISCUSSION: SCD and MNPD offer a powerful approach for risk stratification in preclinical AD, which can improve clinical trial designs, risk counseling, and future case identifications for early treatment.